Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.
Van Der Flier
W M
WM
Alzheimer Center/ Dpt Neurology, VU University Medical Center. wm.vdflier@vumc.nl
Scheltens
P
P
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D001284:Atrophy / Q000473:pathology*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic / Q000379:methods; D018450:Disease Progression; D006801:Humans; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D012107:Research Design
D016229:Amyloid beta-Peptides; D015415:Biomarkers